This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Holding Centene (CNC) in Your Portfolio is a Smart Move
by Zacks Equity Research
Banking on a robust portfolio, buyouts and alliances plus contract wins, Centene (CNC) holds prospects to reap benefits for investors.
Why Holding Anthem (ANTM) in Your Portfolio is a Prudent Move
by Zacks Equity Research
Riding high on better membership, a robust portfolio and operational excellence, Anthem (ANTM) holds potential to reap benefits for investors.
Here's Why Ensign Group (ENSG) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
HCA Healthcare (HCA) Up 43.1% in a Year: Is More Upside Left?
by Zacks Equity Research
Growing revenues, numerous acquisitions and a sturdy financial standing continue to drive HCA Healthcare (HCA).
Ensign Group (ENSG) Up 9.9% in 3 Months: More Room to Grow?
by Zacks Equity Research
Ensign Group (ENSG) expects annual revenues for 2022 in the band of $2.93-$2.98 billion, whose midpoint signals a 12.4% rise from the 2021 reported figure.
Tenet Healthcare (THC) Up 55% in a Year: Is More Upside Left?
by Zacks Equity Research
Growing revenues, strong performances exhibited by segments, numerous acquisitions and sturdy financial standing continue to drive Tenet Healthcare (THC).
Ensign Group (ENSG) Up 8.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Ensign Group (ENSG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ensign Group (ENSG) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Ensign Group (ENSG) on Buyout Binge for Portfolio Boost
by Zacks Equity Research
Ensign Group (ENSG) buys facilities to expand its presence in Arizona and Texas.
Has Ensign Group (ENSG) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Ensign Group (ENSG) and GT Biopharma, Inc. (GTBP) have performed compared to their sector so far this year.
Tenet Healthcare (THC) Drops Plans to Spin Off Conifer Segment
by Zacks Equity Research
Tenet Healthcare (THC) aborts its Conifer spin-off plan based on its solid business opportunities and strong pipeline prospects. It also reaffirmed its 2022 guidance.
Ensign Group (ENSG) Q4 Earnings Match Estimates, Rise Y/Y
by Zacks Equity Research
Ensign Group's (ENSG) Q4 results reflect higher revenues, partly offset by steep expenses.
Molina Healthcare (MOH) Q4 Earnings Beat on Higher Premiums
by Zacks Equity Research
Molina Healthcare (MOH) expects its 2022 business to witness reduced impacts from COVID. Strong Medicare and Medicaid performance is set to buoy results.
Ensign Group (ENSG) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Ensign Group (ENSG) delivered earnings and revenue surprises of 1.04% and 0.79%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Mednax (MD) Buys Night Lite Pediatrics to Boost Portfolio
by Zacks Equity Research
Mednax (MD) purchases Night Lite Pediatrics, LLC in Orlando to enhance its pediatric business line.
Ensign Group (ENSG) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Ensign Group (ENSG), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Ensign Group (ENSG) Buys Facilities to Expand in California
by Zacks Equity Research
Ensign Group (ENSG) further expands in California by purchasing the operations of Arrowhead Springs Healthcare, San Bernardino, CL and Desert Mountain Care Center, Indio, CL.
Here is Why Growth Investors Should Buy Ensign Group (ENSG) Now
by Zacks Equity Research
Ensign Group (ENSG) could produce exceptional returns because of its solid growth attributes.
Humana (HUM) Q4 Earnings Beat Estimates on Membership Growth
by Zacks Equity Research
Humana (HUM) is taking multiple initiatives like cost savings and others to generate $1 billion additional value to fund the Medicare Advantage business and boost Healthcare Services capabilities.
Ensign Group (ENSG) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Ensign Group (ENSG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Encompass Health (EHC) to Spin Off Home Health & Hospice Unit
by Zacks Equity Research
Encompass Health (EHC) expects the Enhabit Home Health & Hospice spinoff to be completed in first-half 2022.
Ensign Group (ENSG) Up 7.4% in 3 Months: More Growth Ahead?
by Zacks Equity Research
Ensign Group (ENSG) is likely to keep growing on the back of Skilled services and impressive financial strength.
Ensign Group (ENSG) Buys Nursing Facility to Expand in Arizona
by Zacks Equity Research
Ensign Group (ENSG) acquires operations of Estrella Health and Rehabilitation Center in Arizona to grow its portfolio and boost U.S. presence.
Ensign Group (ENSG) Hikes Dividend to Share More Profits
by Zacks Equity Research
Ensign Group's (ENSG) dividend hike reflects its intention to enhance shareholders' value supported by its strong financial position.
Here's Why Investors Should Hold Onto Ensign Group (ENSG)
by Zacks Equity Research
Riding high on a solid portfolio and a rising top line, Ensign Group (ENSG) holds enough potential to reap benefits for investors.